GLP-1 Side Effects, Week by Week: What to Expect and When

The most common question before starting a GLP-1 isn’t “will it work?” — it’s “how bad will I feel, and for how long?” There’s no single answer that fits everyone, but there is a recognizable shape to the experience. Knowing the timeline turns scary surprises into expected milestones.

Two things frame everything below. First, side effects cluster around starting and dose increases, then fade as your body adapts — they track titration, not calendar weeks. Second, a large share of people get only mild effects or breeze through entirely; the trial dropout rate from side effects was a small minority. This is what can happen, not what will.

Week 1: the introduction

You start at the lowest dose — deliberately too low to do much for weight, precisely so your body can meet the drug gently.

• What’s common: mild nausea (especially after big or fatty meals), early fullness, maybe some constipation or reflux. Some people feel almost nothing at the starter dose.
• What surprises people: the appetite change can arrive fast — quieter food noise within days for some, well before any weight moves.
• What to do: start the habits now, before you need them — smaller portions, less fat, sip water all day, and stop eating at the first fullness signal.

Weeks 2–4: settling in

For many, the first dose’s side effects ease over these weeks as the stomach adapts to slower emptying. This is the “oh, I can do this” stretch — appetite suppression is working, side effects are calming. Weight loss is usually modest at the starter dose; that’s expected, not failure.

The dose-increase pattern (repeats each step)

Here’s the single most useful thing to internalize: each dose increase can feel like a smaller version of week 1. Titration steps are typically spaced 4 weeks apart, and nausea or GI effects often flare for a few days after each step up, then settle.

• The flares usually shrink with each step as your baseline tolerance builds — but not always, and not for everyone.
• If a step is genuinely rough, prescribers routinely hold you at the current dose longer or step back down. That’s normal management, not a setback (see titration).
• This is exactly why logging side effects against your dose changes is worth it: “3 rough days after each increase, then fine” reads completely differently from “nauseous all month.”

Months 2–4: the adaptation window

By now most people have found their rhythm. A few effects have a delayed onset worth flagging so they don’t blindside you:

• Hair shedding can appear 2–4 months in — driven by rapid weight loss, not the drug directly, and temporary.
• Fatigue sometimes shows up here if you’ve been undereating or underhydrating.
• Gallstone risk rises with rapid weight loss over these months.

Appetite suppression is usually strong and steady through this window — the period of fastest weight change for most people.

Months 6+ and maintenance: the long plateau

Side effects are typically minimal by now — your body has adapted. The story shifts from “managing symptoms” to “sustaining results”: appetite suppression may soften slightly, weight loss flattens into the expected plateau, and the focus moves to protein, muscle, and habits. Most people on maintenance tolerate their dose comfortably.

Red flags at every stage

Most GLP-1 discomfort is mild and dose-related. These are the exceptions that warrant a prompt call rather than waiting it out — at any point in the timeline:

• Severe abdominal pain, especially radiating to the back (pancreatitis is rare but serious).
• Vomiting that won’t stop, or inability to keep fluids down (dehydration, or a dose too high for you — see gastroparesis).
• Right-upper-belly pain, fever, or yellowing skin (gallstones).
• Signs of low blood sugar if you also take insulin or a sulfonylurea.

The takeaway

The GLP-1 side-effect experience is front-loaded and step-loaded: hardest near the start and after increases, easier in between and over time. Tracking symptoms against your dose — which the shot-day routine builds in — is what turns a vague, anxious “am I okay?” into a clear pattern you and your prescriber can actually act on.

Sources: STEP 1 trial (Wilding et al., NEJM 2021, adverse-event tables); SURMOUNT-1 trial (Jastreboff et al., NEJM 2022); Wegovy and Zepbound prescribing information.